Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma Editorial

  


Authors: Smithy, J. W.; Postow, M. A.
Title: Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma
Abstract: Combinatorial immunotherapy may improve the efficacy of neoadjuvant checkpoint inhibitors in locoregionally advanced melanoma. In this issue of Cancer Cell, Davar and colleagues report a promising phase 2 neoadjuvant trial of the TLR9 agonist vidutolimod in combination with nivolumab. Analyses suggest a unique myeloid expression signature is associated with response. © 2024 Elsevier Inc.
Keywords: treatment response; advanced cancer; cancer combination chemotherapy; drug efficacy; note; antineoplastic agent; cancer immunotherapy; melanoma; antineoplastic combined chemotherapy protocols; pathology; drug therapy; toll-like receptor 9; programmed death 1 receptor; toll like receptor 9; phase 2 clinical trial (topic); immune checkpoint inhibitor; nivolumab; oximes; humans; human; rna sequencing; pdcd1 protein, human; programmed cell death 1 receptor; immune checkpoint inhibitors; oxime; vidutolimod
Journal Title: Cancer Cell
Volume: 42
Issue: 11
ISSN: 1535-6108
Publisher: Cell Press  
Date Published: 2024-11-11
Start Page: 1813
End Page: 1814
Language: English
DOI: 10.1016/j.ccell.2024.10.001
PUBMED: 39486410
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85208181872&doi=10.1016%2fj.ccell.2024.10.001&partnerID=40&md5=4089682797209f9d9f56b49dde68a343
Notes: Note -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Michael Andrew Postow
    361 Postow
  2. James William Smithy
    28 Smithy
Related MSK Work